Our Mission

We believe Ethereum will play a key role
in the global financial system.

Everyone deserves access to the emerging onchain economy.

As Ethereum evolves towards being the financial system’s settlement layer, we believe opportunities for superior yields will emerge... for those who know where to look.

Through its unique strategies and access to capital markets, ETHZilla aims to accumulate more ETH per share over time - giving investors increased exposure to one of the most important assets in the world.

Our Strategy

To achieve our mission, ETH must be more than just held: it must be staked, restaked, and strategically deployed throughout the onchain economy.

By partnering with some of the world's top yield generation experts, we plan to put our ETH to work, supplementing staking yields with additional onchain strategies.

Our first partner is Electric Capital. We are looking forward to having more onchain partners to support the Ethereum ecosystem.

Our Operations

180 Life Sciences is adopting an innovative Ethereum Treasury Strategy, expanding into digital asset infrastructure and onchain capital innovation. Going forward, the company plans to operate as ETHZilla, signaling a shift toward Ethereum-native investments and deep alignment with what we believe is the future of the global financial system.

Biotech and Gaming Operations
In addition to its existing biotech assets, 180 Life Sciences continues to maintain and accelerate the deployment and development of its gaming initiatives, opening additional avenues for value creation.

Blair Jordan

CEO & Director

Blair Jordan is Co-Founder and CEO of HighMont Advisors, a global strategy and finance firm specializing in corporate transitions. He brings extensive board experience across public and private companies, serving on the boards and audit, governance and special committees of Goldgroup Mining, Standard Uranium, and Timeless Capital. With prior senior executive roles including CEO, CFO and Management Committee at various public and private companies, his experience spans mining, technology, health sciences, aviation, and finance. He holds an MBA from the University of Chicago Booth School, an LL.B. from UBC, and a BA from the University of Victoria.

McAndrew Rudisill

Incoming Chairman & Director

Founder and Managing Partner of Harbour Island LLC. Strategic Advisor to Etherealize. Former Chief Investment Officer and Director of Bridger Aerospace. Entrepreneur and investor with a track record of founding and monetizing businesses across specialty aviation, counter-UAS technology, fractional resorts, consumer finance, oil & gas infrastructure, and large-scale multifamily housing. Founder of Pelagic Capital Advisors LLC. BA Cum Laude from Middlebury College.

Stephen Shoemaker

Independent Director

Mr. Shoemaker is a senior executive with over two decades of leadership in iGaming, hospitality, tech, and real estate. He has raised over $2 billion in CEO and CFO roles, with expertise in strategic planning, capital markets, and operations across North America, Asia, and Europe. Most recently, he served as CEO of WIN Group (2021–2024), a global esports betting company, where he doubled content platform users and launched a licensed iGaming platform. Prior roles include CEO of Engine Media Holdings (TSX/NASDAQ: GAME), where he drove capital raises and revenue growth, and senior leadership at Asian Coast Development, NuVox, GT Group Telecom, and Qwest Communications. He holds a B.S. in Commerce from the University of Virginia and is a CPA.

Ryan Smith

Lead Independent Director

Mr. Smith has served as CEO and President of U.S. Energy Corp (Nasdaq: USEG) since December 2019, and was previously CFO from 2017 to 2023. Before joining U.S. Energy, he held CFO and VP roles at Emerald Oil (2013–2017) and was a VP in Canaccord Genuity's Energy Investment Banking Group (2008–2013), leading financing and M&A transactions. He began his career as an analyst in Wells Fargo's Energy Group. Mr. Smith holds a BBA in Finance from Texas A&M University.

Lawrence Steinman

Director

Professor Lawrence Steinman is currently the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University. His specialities lie in autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. In the Steinman Laboratory of Stanford, which is his foundation, he has developed new therapies for autoimmune diseases, some of which are in advanced clinical trials.

ETHzilla